Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Olverembatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olverembatinib Data Reaffirms Potential in Ponatinib Resistance
    Olverembatinib Data Reaffirms Potential in Ponatinib Resistance

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--1-5-year-follow-up-data-from-a-global-study-of-olverembatinib-reaffirms-potential-in-overcoming-resistanceintolerance-to-ponatinib-or-asciminib-302327550.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL
    1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--1st-dataset-of-olverembatinib-in-combination-with-bcl-2-inhibitor-lisaftoclax-demonstrates-potential-clinical-benefits-as-a-chemotherapy-free-regimen-for-children-with-rr-ph-all-302327474.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    Olverembatinib Overcomes CML Resistance, Well Tolerated in Report
    Olverembatinib Overcomes CML Resistance, Well Tolerated in Report

    21 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/olverembatinib-surmounts-ponatinib-and-asciminib-resistance-and-is-well-tolerated-in-patients-with-cml-and-ph-all-new-report-in-jama-oncology-302313802.html

    PR NEWSWIRE
    21 Nov 2024
    Share Share
    ASH 2024: Olverembatinib Data Selected for Oral Presentation
    ASH 2024: Olverembatinib Data Selected for Oral Presentation

    06 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ash-2024--studies-of-olverembatinib-selected-for-presentations-including-an-oral-report-for-the-seventh-consecutive-year-302297311.html

    PR NEWSWIRE
    06 Nov 2024
    Share Share
    Ascentage Pharma Releases Olverembatinib Data In SDH-Deficient GIST
    Ascentage Pharma Releases Olverembatinib Data In SDH-Deficient GIST

    13 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-esmo-2024--ascentage-pharma-releases-latest-data-showing-sustained-clinical-efficacy-of-olverembatinib-in-sdh-deficient-gist-during-a-mini-oral-presentation-302248193.html

    PR NEWSWIRE
    13 Sep 2024
    Share Share
    Olverembatinib Approved for Commercialization in Macau China
    Olverembatinib Approved for Commercialization in Macau China

    07 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/olverembatinib-approved-for-commercialization-in-macau-china-302190451.html

    PR NEWSWIRE
    07 Jul 2024
    Share Share